BOSTON, March 02, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. GLTOa clinical-stage biotechnology company and global leader in galectin biology focused on developing novel treatments for fibrosis and cancer, announced today that management will be presenting and available for 1×1 meetings at Oppenheimer’s 33approx Annual health conference taking place virtually on March 13-15, 2023. Details for the event are as follows:
| Oppenheimer 33approx Annual Health Conference | |
| Date: | Monday March 13, 2023 |
| Time: | 9:20 a.m. EST |
| web cast: | Click here |
A live webcast of the presentation will be available on the News & Events section of Galecto’s investor website at https://ir.galecto.com/news-and-events/events. A recording of the presentation will be available on the same website after the event.
About Galecto
Galecto is a US registered clinical-stage company developing small molecule inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 study for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a recently completed phase 1b/2a study in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate Phase 2 study for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).
Galecto intends to use its website as a means of disclosing material non-public information. Visit for regular updates about Galecto www.galecto.com.
For more information contact:
| Galecto, Inc. | |
| Hans Schambye, Managing Director Jon Freve, Chief Financial Officer |
|
| +45 70 70 52 10 | |
| Investors/USA | Media/EU |
| Ashley R Robinson arr@lifesciadvisors.com |
Sandya from the Weid svonderweid@lifesciadvisors.com |
| +1 617 430 7577 | +41 78 680 0538 |
[ad_2]
Source story
